Why Blackstone’s $250M Investment in Autolus Is Necessary for Obe-cel’s Clinical Development
On Monday, November 8, Autolus announced (press release) that they have entered into a collaboration and financing agreement with Blackstone Life Sciences for the development of obe-cel (CD19 CAR-T, formerly AUTO1) and obe-cel’s next-generation therapies in B cell malignancies. Below, Celltelligence provides insights on how Autolus’s collaboration with Blackstone could secure obe-cel’s clinical development while giving the company flexibility to develop other assets within their pipeline.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.